Porcine Vaccines Market - Snapshot
The global porcine vaccines market is expanding due to growing prevalence of swine diseases across the globe. The global porcine vaccines market was valued at US$ 1,784.0 Mn in 2016 and is projected to expand at a compounded annual growth rate (CAGR) of over 7.0% from 2017 to 2025, to reach value of US$ 3,208.8 Mn by 2025. The global market is witnessing growth at a relatively high rate, owing to rise in investments by governments in the field of animal health care, high incidence of swine fever, increase in R&D expenses incurred for eradicating porcine health issues, and surge in the demand for porcine meat and gelatin.
Porcine vaccine is an administrative as well as clinical drug that helps in improving health of swine and protects them from deadly viruses, bacteria, and pathogens. Diseases such as diarrhea, swine influenza, porcine reproductive and respiratory syndrome, and porcine circovirus associated disease (PCVAD) have been greatly reduced from spreading in an endemic manner. A few diseases such as foot & mouth disease and cholera high fever have been eliminated in swine in North America and Europe through vaccination. The success of animal vaccination remains as an ideal interval for booster vaccination.
A porcine vaccine aids the swine or hogs suffering from epidemic porcine diseases. It also improves overall efficiency in protecting pigs from deadly viruses and increases the production level of high-quality meat for consumption. High prevalence and incidence rates of porcine epidemic diarrhea (PED), swine flu, and porcine reproductive and respiratory syndrome (PRRS) in swine production farms worldwide have resulted in increase in early vaccination of piglets and adult pigs. There has been increase in the number of awareness programs about porcine diseases and rise in the number of joint venture programs by key players in different regions for research and development of swine vaccines. These factors are collectively projected to drive the demand for porcine vaccines across the world in the near future. Also, technological advancements such as combined vaccine production and DNA vaccines enable agriculture farmers to produce disease-free pigs. This factor is estimated to fuel the porcine vaccines market in the near future.
The global porcine vaccines market has been broadly segmented based on technology, disease indication, end-user, and region. In terms of technology, the global market has been categorized into inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines. The inactivated vaccines segment accounted for a key share (in terms of revenue) of the global market in 2016. The live attenuated vaccines segment is estimated to expand at a significant growth rate during the forecast period and is estimated to gain a significant market share by 2025. DNA vaccines also offer several advantages over live attenuated vaccines and inactivated vaccines and thus, DNA vaccines are increasingly gaining popularity among veterinary hospitals and hog production farms.
In terms of disease indication, the global porcine vaccines market has been divided into diarrhea, swine influenza, arthritis, Bordetella rhinitis, porcine reproductive and respiratory syndrome (PRRS), porcine circovirus associated disease (PCVAD), and others (CHRS, leptospirosis, etc.). Diarrhea and swine influenza segments dominated the global market in 2016 and are likely to continue their dominance from 2017 to 2025, with a marginal increase in their market shares by 2025. Increasing production of pigs in farms for meat, gelatin, and other products; changes in climate including global warming; overfeeding of protein diet; and increasing occurrence of genetically modified strains of influenza viruses have led to significant shares held by diarrhea and swine influenza segments in the global market. In terms of end-user, the global market has been divided into veterinary hospitals and hog production farms. The hog production farms segment is estimated to gain a significant market share by 2025, due to increasing demand for production of pigs for meat and other products.
Geographically, the global porcine vaccines market has been segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2016 and is projected to lose market share by 2025. The market in North America is primarily driven by rapid increase in pig cultivation and rise in infection of pigs caused by viruses such as PEDV, PCV, and PRRSV in the U.S. Moreover, rise in contract farming and independent farming for pig production has been observed in the U.S., which is projected to fuel the hog production farms segment of the market in the U.S. during the forecast period. Asia Pacific is projected to be a rapidly expanding market for porcine vaccines during the forecast period. China dominates the porcine vaccines market in Asia Pacific. The market in Rest of Asia Pacific (including Vietnam, the Philippines, etc.) is estimated to expand at a significant CAGR during the forecast period.
Companies such as Boehringer Ingelheim GmbH, Ceva Santé Animale, Elanco (Eli Lilly and Company), Merck & Co., Inc., and Zoetis, Inc. were major players in the global porcine vaccines market in 2016. Zoetis, Inc. dominated the market with its diversified product portfolio, extensive geographical presence, and acquisition strategies. In 2015, the company invested over US$ 1.0 Bn in two largest acquisitions. One of them was the acquisition of PHARMAQ, which strengthened Zoetis’ core livestock business division. Other players operating in the global market include Bimeda Animal Health, Vetoquinol, and Bayer AG. Companies are adopting the strategy of acquisitions and collaborations to enhance and strengthen their geographical presence.
Growing Awareness about Improving the Health of Pigs to Bring Tremendous Growth Opportunities for the Porcine Vaccine Market
The prevalence of diseases and disorders among animals caused due to various types of viruses and bacteria has led to a massive number of fatalities. The growing influence of these diseases due to the viruses and bacteria and the rising awareness among a large chunk of the populace in terms of vaccinating the animals to protect them will serve as a prominent growth factor for the porcine vaccine market during the forecast period of 2016-2024.
The global porcine vaccines market has been segmented as below:
|
by Disease |
|
|
by Technology |
|
|
by End-user |
|
|
by Geography |
|
Chapter 1.Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2.Assumptions and Research Methodology
Chapter 3.Executive Summary : Global Porcine Vaccines Market
Chapter 4.Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Market Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Porcine Vaccines Market Analysis and Forecast, 2015–2025
4.4.1. Market Revenue Projection (US$ Mn)
4.5. Porter’s Five Forces Analysis
4.6. Market Outlook
4.7.Regulatory Scenario Assessment
4.7.1. North America
4.7.2. Europe
4.7.3. Asia Pacific
4.8.Disease Indication Comparison, by Region
4.8.1. North America
4.8.2. Europe
4.8.3. Asia Pacific
4.8.4. Latin America
4.8.5. Middle East & Africa
4.9.Swine Production Level, by Region/State
4.9.1. North America
4.9.2. Europe
4.9.3. Asia Pacific
4.9.4. Latin America
4.10.Product Launches and Innovations
4.11. Recent Market Activities
4.12.Introduction of New Types of Vaccines
4.13. Snapshot of Market Trends and Issues
Chapter 5.Global Porcine Vaccines Market Analysis and Forecast, by End-user
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Market Value Forecast by End-user, 2015–2025
5.3.1. Inactivated Vaccines
5.3.2. Live Attenuated Vaccines
5.3.3. Toxoid Vaccines
5.3.4. Recombinant Vaccines
5.3.5. Conjugate Vaccines
5.3.6. DNA Vaccines
5.4. Market Attractiveness, by End-user
Chapter 6.Global Porcine Vaccines Market Analysis and Forecast, by Disease Indication
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Disease Indication, 2015–2025
6.3.1. Diarrhea
6.3.2. Swine Influenza
6.3.3. Arthritis
6.3.4. Bordetella Rhinitis
6.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS)
6.3.6. Porcine Circovirus Associated Disease (PCVAD)
6.3.7. Others
6.4. Market Attractiveness, by Disease Indication
Chapter 7.Global Porcine Vaccines Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2015–2025
7.3.1. Veterinary Hospitals
7.3.2. Hog Production Farms
7.4. Market Attractiveness, by End-user
Chapter 8.Global Porcine Vaccines Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
Chapter 9.North America Porcine Vaccines Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by End-user, 2015–2025
9.2.1. Inactivated Vaccines
9.2.2. Live Attenuated Vaccines
9.2.3. Toxoid Vaccines
9.2.4. Recombinant Vaccines
9.2.5. Conjugate Vaccines
9.2.6. DNA Vaccines
9.3. Market Value Forecast, by Disease Indication, 2015–2025
9.3.1. Diarrhea
9.3.2. Swine Influenza
9.3.3. Arthritis
9.3.4. Bordetella Rhinitis
9.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS)
9.3.6. Porcine Circovirus Associated Disease (PCVAD)
9.3.7. Others
9.4. Market Value Forecast, by End-user, 2015–2025
9.4.1. Veterinary Hospitals
9.4.2. Hog Production Farms
9.5. Market Value Forecast, by Country, 2015–2025
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By End-user
9.6.2. By Disease Indication
9.6.3. By End-user
9.6.4. By Country
Chapter 10.Europe Porcine Vaccines Market Analysis and Forecast
10.1.Introduction
10.1.1. Key Findings
10.2.Market Value Forecast, by End-user, 2015–2025
10.2.1. Inactivated Vaccines
10.2.2. Live Attenuated Vaccines
10.2.3. Toxoid Vaccines
10.2.4. Recombinant Vaccines
10.2.5. Conjugate Vaccines
10.2.6. DNA Vaccines
10.3.Market Value Forecast, by Disease Indication, 2015–2025
10.3.1. Diarrhea
10.3.2. Swine Influenza
10.3.3. Arthritis
10.3.4. Bordetella Rhinitis
10.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS)
10.3.6. Porcine Circovirus Associated Disease (PCVAD)
10.3.7. Others
10.4.Market Value Forecast, by End-user, 2015–2025
10.4.1. Veterinary Hospitals
10.4.2. Hog Production Farms
10.5.Market Value Forecast, by Country/Sub-region, 2015–2025
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Spain
10.5.5. Italy
10.5.6. Russia
10.5.7. Rest of Europe
10.6.Market Attractiveness Analysis
10.6.1. By End-user
10.6.2. By Disease Indication
10.6.3. By End-user
10.6.4. By Country/Sub-region
Chapter 11.Asia Pacific Porcine Vaccines Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by End-user, 2015–2025
11.2.1. Inactivated Vaccines
11.2.2. Live Attenuated Vaccines
11.2.3. Toxoid Vaccines
11.2.4. Recombinant Vaccines
11.2.5. Conjugate Vaccines
11.2.6. DNA Vaccines
11.3.Market Value Forecast, by Disease Indication, 2015–2025
11.3.1. Diarrhea
11.3.2. Swine Influenza
11.3.3. Arthritis
11.3.4. Bordetella Rhinitis
11.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS)
11.3.6. Porcine Circovirus Associated Disease (PCVAD)
11.3.7. Others
11.4.Market Value Forecast, by End-user, 2015–2025
11.4.1. Veterinary Hospitals
11.4.2. Hog Production Farms
11.5.Market Value Forecast, by Country/Sub-region, 2015–2025
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6.Market Attractiveness Analysis
11.6.1. By End-user
11.6.2. By Disease Indication
11.6.3. By End-user
11.6.4. By Country/Sub-region
Chapter 12.Latin America Porcine Vaccines Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Value Forecast, by End-user, 2015–2025
12.2.1. Inactivated Vaccines
12.2.2. Live Attenuated Vaccines
12.2.3. Toxoid Vaccines
12.2.4. Recombinant Vaccines
12.2.5. Conjugate Vaccines
12.2.6. DNA Vaccines
12.3.Market Value Forecast, by Disease Indication, 2015–2025
12.3.1. Diarrhea
12.3.2. Swine Influenza
12.3.3. Arthritis
12.3.4. Bordetella Rhinitis
12.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS)
12.3.6. Porcine Circovirus Associated Disease (PCVAD)
12.3.7. Others
12.4.Market Value Forecast, by End-user, 2015–2025
12.4.1. Veterinary Hospitals
12.4.2. Hog Production Farms
12.5.Market Value Forecast, by Country/Sub-region, 2015–2025
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6.Market Attractiveness Analysis
12.6.1. By End-user
12.6.2. By Disease Indication
12.6.3. By End-user
12.6.4. By Country/Sub-region
Chapter 13.Middle East & Africa Porcine Vaccines Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Value Forecast, by End-user, 2015–2025
13.2.1. Inactivated Vaccines
13.2.2. Live Attenuated Vaccines
13.2.3. Toxoid Vaccines
13.2.4. Recombinant Vaccines
13.2.5. Conjugate Vaccines
13.2.6. DNA Vaccines
13.3.Market Value Forecast, by Disease Indication, 2015–2025
13.3.1. Diarrhea
13.3.2. Swine Influenza
13.3.3. Arthritis
13.3.4. Bordetella Rhinitis
13.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS)
13.3.6. Porcine Circovirus Associated Disease (PCVAD)
13.3.7. Others
13.4.Market Value Forecast, by End-user, 2015–2025
13.4.1. Veterinary Hospitals
13.4.2. Hog Production Farms
13.5.Market Value Forecast, by Country/Sub-region, 2015–2025
13.5.1. South Africa
13.5.2. Rest of Middle East & Africa
13.6.Market Attractiveness Analysis
13.6.1. By End-user
13.6.2. By Disease Indication
13.6.3. By End-user
13.6.4. By Country/Sub-region
Chapter 14.Competition Landscape
14.1.Market Player – Competition Matrix (by Tier and Size of companies)
14.2.Market Share Analysis, by Company (2016)
14.2.1. Bayer AG
14.2.1.1. Overview
14.2.1.2. Financials
14.2.1.3. Recent Developments
14.2.1.4. Strategy
14.2.2. Bimeda Animal Health
14.2.2.1. Overview
14.2.2.2. Financials
14.2.2.3. Recent Developments
14.2.2.4. Strategy
14.2.2. Boehringer Ingelheim GmbH
14.2.3.1. Overview
14.2.3.2. Financials
14.2.3.3. Recent Developments
14.2.3.4. Strategy
14.2.4. Ceva Santé Animale
14.2.4.1. Overview
14.2.4.2. Financials
14.2.4.3. Recent Developments
14.2.4.4. Strategy
14.2.5. Elanco (Eli Lilly and Company)
14.2.5.1. Overview
14.2.5.2. Financials
14.2.5.3. Recent Developments
14.2.5.4. Strategy
14.2.6. Merck & Co., Inc.
14.2.6.1. Overview
14.2.6.2. Financials
14.2.6.3. Recent Developments
14.2.6.4. Strategy
14.2.7. Vetoquinol
14.2.7.1. Overview
14.2.7.2. Financials
14.2.7.3. Recent Developments
14.2.7.4. Strategy
14.2.8. Zoetis, Inc.
14.2.8.1. Overview
14.2.8.2. Financials
14.2.8.3. Recent Developments
14.2.8.4. Strategy
14.2.9. Others
List of Tables
Table 01: Global Porcine Vaccines Market Size (US$ Mn) Forecast, by Technology, 2015–2025
Table 02: Global Porcine Vaccines Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 03: Global Porcine Vaccines Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 04: Global Porcine Vaccines Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 05: North America Porcine Vaccines Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 06: North America Porcine Vaccines Market Size (US$ Mn) Forecast, by Technology, 2015–2025
Table 07: North America Porcine Vaccines Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 08: North America Porcine Vaccines Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 09: Europe Porcine Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 10: Europe Porcine Vaccines Market Size (US$ Mn) Forecast, by Technology, 2015–2025
Table 11: Europe Porcine Vaccines Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 12: Europe Porcine Vaccines Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 13: Asia Pacific Porcine Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 14: Asia Pacific Porcine Vaccines Market Size (US$ Mn) Forecast, by Technology, 2015–2025
Table 15: Asia Pacific Porcine Vaccines Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 16: Asia Pacific Porcine Vaccines Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 17: Latin America Porcine Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 18: Latin America Porcine Vaccines Market Size (US$ Mn) Forecast, by Technology, 2015–2025
Table 19: Latin America Porcine Vaccines Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 20: Latin America Porcine Vaccines Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 21: Middle East & Africa Porcine Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 22: Middle East & Africa Porcine Vaccines Market Size (US$ Mn) Forecast, by Technology, 2015–2025
Table 23: Middle East & Africa Porcine Vaccines Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 24: Middle East & Africa Porcine Vaccines Market Size (US$ Mn) Forecast, by End-user, 2015–2025
List of Figures
FIG 01: Global Porcine Vaccines Market Size (US$ Mn) Forecast, 2015–2025
FIG 02: Global Porcine Vaccines Market Value Share, by Technology (2016)
FIG 03: Global Porcine Vaccines Market Value Share, by Region (2016)
FIG 04: Global Porcine Vaccines Market Value Share, by End-user (2016)
FIG 05: Global Porcine Vaccines Market Value Share, by Disease Indication (2016)
FIG 06: Global Porcine Vaccines Market Value Share, by Technology, 2017 and 2025
FIG 07: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Inactivated Vaccines, 2015–2025
FIG 08: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Live Attenuated Vaccines, 2015–2025
FIG 09: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Toxoid Vaccines, 2015–2025
FIG 10: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Recombinant Vaccines, 2015–2025
FIG 11: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Conjugate Vaccines, 2015–2025
FIG 12: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by DNA Vaccines, 2015–2025
FIG 13: Global Porcine Vaccines Market Attractiveness, by Technology, 2017–2025
FIG 14: Global Porcine Vaccines Market Value Share, by Disease Indication, 2017 and 2025
FIG 15: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Diarrhea, 2015–2025
FIG 16: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Swine Influenza, 2015–2025
FIG 17: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Arthritis, 2015–2025
FIG 18: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Bordetella Rhinitis, 2015–2025
FIG 19: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by PRRS, 2015–2025
FIG 20: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by PCVAD, 2015–2025
FIG 21: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2015–2025
FIG 22: Global Porcine Vaccines Market Attractiveness, by Disease Indication, 2017–2025
FIG 23: Global Porcine Vaccines Market Value Share, by End-user, 2017 and 2025
FIG 24: Global Porcine Vaccines Market Attractiveness, by End-user, 2017–2025
FIG 25: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Veterinary Hospitals, 2015–2025
FIG 26: Global Porcine Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hog Production Farms, 2015–2025
FIG 27: Global Porcine Vaccines Market Value Share, by Region, 2017 and 2025
FIG 28: Global Porcine Vaccines Market Attractiveness, by Region, 2017–2025
FIG 29: North America Porcine Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
FIG 30: North America Porcine Vaccines Market Attractiveness, by Country, 2017–2025
FIG 31: North America Porcine Vaccines Market Value Share Analysis, by Country, 2017 and 2025
FIG 32: North America Porcine Vaccines Market Value Share, by Technology, 2017 and 2025
FIG 33: North America Porcine Vaccines Market Value Share, by Disease Indication, 2017 and 2025
FIG 34: North America Porcine Vaccines Market Value Share, by End-user, 2017 and 2025
FIG 35: North America Porcine Vaccines Market Attractiveness Analysis, by Technology, 2017–2025
FIG 36: North America Porcine Vaccines Market Attractiveness Analysis, by Disease Indication, 2017–2025
FIG 37: North America Porcine Vaccines Market Attractiveness Analysis, by End-user, 2017–2025
FIG 38: North America Swine Production Level, by Top Countries/States
FIG 39: Europe Porcine Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
FIG 40: Europe Porcine Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
FIG 41: Europe Porcine Vaccines Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
FIG 41: Europe Porcine Vaccines Market Value Share, by Technology, 2017 and 2025
FIG 43: Europe Porcine Vaccines Market Value Share, by Disease Indication, 2017 and 2025
FIG 44: Europe Porcine Vaccines Market Value Share, by End-user, 2017 and 2025
FIG 45: Europe Porcine Vaccines Market Attractiveness Analysis, by Technology, 2017–2025
FIG 46: Europe Porcine Vaccines Market Attractiveness Analysis, by Disease Indication, 2017–2025
FIG 47: Europe Porcine Vaccines Market Attractiveness Analysis, by End-user, 2017–2025
FIG 48: Europe Swine Production Level, by Top Countries/States
FIG 49: Asia Pacific Porcine Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
FIG 50: Asia Pacific Porcine Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
FIG 51: Asia Pacific Porcine Vaccines Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
FIG 52: Asia Pacific Porcine Vaccines Market Value Share, by Technology, 2017 and 2025
FIG 53: Asia Pacific Porcine Vaccines Market Value Share, by Disease Indication, 2017 and 2025
FIG 54: Asia Pacific Porcine Vaccines Market Value Share, by End-user, 2017 and 2025
FIG 55: Asia Pacific Porcine Vaccines Market Attractiveness Analysis, by Technology, 2017–2025
FIG 56: Asia Pacific Porcine Vaccines Market Attractiveness Analysis, by Disease Indication, 2017–2025
FIG 57: Asia Pacific Porcine Vaccines Market Attractiveness Analysis, by End-user, 2017–2025
FIG 58: Asia Pacific Swine Production Level, by Top Countries/States
FIG 59: Latin America Porcine Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
FIG 60: Latin America Porcine Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
FIG 61: Latin America Porcine Vaccines Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
FIG 62: Latin America Porcine Vaccines Market Value Share, by Technology, 2017 and 2025
FIG 63: Latin America Porcine Vaccines Market Value Share, by Disease Indication, 2017 and 2025
FIG 64: Latin America Porcine Vaccines Market Value Share, by End-user, 2017 and 2025
FIG 65: Latin America Porcine Vaccines Market Attractiveness Analysis, by Technology, 2017–2025
FIG 66: Latin America Porcine Vaccines Market Attractiveness Analysis, by Disease Indication, 2017–2025
FIG 67: Latin America Porcine Vaccines Market Attractiveness Analysis, by End-user, 2017–2025
FIG 68: Latin America Swine Production Level, by Top Countries/States
FIG 69: Middle East & Africa Porcine Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
FIG 70: Middle East & Africa Porcine Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
FIG 71: Middle East & Africa Porcine Vaccines Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
FIG 72: Middle East & Africa Porcine Vaccines Market Value Share, by Technology, 2017 and 2025
FIG 73: Middle East & Africa Porcine Vaccines Market Value Share, by Disease Indication, 2017 and 2025
FIG 74: Middle East & Africa Porcine Vaccines Market Value Share, by End-user, 2017 and 2025
FIG 75: Middle East & Africa Porcine Vaccines Market Attractiveness Analysis, by Technology, 2017–2025
FIG 76: Middle East & Africa Porcine Vaccines Market Attractiveness Analysis, by Disease Indication, 2017–2025
FIG 77: Middle East & Africa Porcine Vaccines Market Attractiveness Analysis, by End-user, 2017–2025
FIG 78: Global Porcine Vaccines Market Share Analysis, by Company, 2016
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Porcine Vaccines Market
*86 figures and 60 tables includes